NEW:   Pathology Grand Rounds Mark Sulkowski, M.D. Presented 04/01/2004 Assistant Professor Johns Hopkins Medical Institutions "Hepatitis C in HIV Infected Persons" AMP 2003 Presentations: Karin Berg MD, MS Real-time PCR Comparison Chart A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter. Claudin 3 and 4 expression in gastric and esophageal cancer New FLT3 Trial Transcription Mediated Amplification Animation bDNA Methodology Animation

New FLT3 Trial Download Requisition Form (pdf) A new trial of the FLT3 inhibitor, CEP701 in AML patients is scheduled to begin at Johns Hopkins in December 2003. Contacts for this important trial: Principal Investigator: B. Doug Smith, MD Kimmel Cancer Center Cancer Research Bldg. 246 1650 Orleans St. Baltimore, MD 21231 Study Coordinator: Tianna Dauses Johns Hopkins Cancer Research Bldg. 1650 Orleans St. Baltimore, MD 21231 410-502-7110 410-502-9690 - Fax dauseti@jhmi.edu FLT3 testing for the CEP701 trial and as a prognostic indicator in AML is available at the Johns Hopkins Molecular Diagnostics Lab. Click here for contact information. For more information on the FLT3 mutation test developed at The Johns Hopkins University School of Medicine by Dr. Kathleen Murphy, see: Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay. J Mol Diagn. 2003 May;5(2):96-102.

Homepage | Site Info | Contact Us | Links | Search

Pathology Homepage Copyright © 1999 - 2005 The Johns Hopkins University All rights reserved. No part of this website may be reproduced in any form or by any means or incorporated into any information retrievel system, electronic or mechanical, without the written permission of JHU.